Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes.
Nonalcoholic fatty liver disease
biomarker
hepatocellular carcinoma
tumor growth rates
Journal
Hepatoma research
ISSN: 2394-5079
Titre abrégé: Hepatoma Res
Pays: United States
ID NLM: 101688384
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
30
12
2021
pubmed:
31
12
2021
medline:
31
12
2021
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is projected to become the leading indication for liver transplantation. Previous studies indicate that tumor growth rates (TGR) may predict survival and were helpful in determining HCC surveillance intervals. Therefore, we aimed to determine its usefulness in predicting clinical outcomes and treatments. We conducted a retrospective study of hepatitis B, C and NAFLD-HCC cases. TGR was measured using 2-consecutive pre-treatment contrast-enhanced imaging studies ≥ 25 days apart. A multivariate regression model was used to determine predictors of TGR. In addition, the Cox regression model was used to evaluate the relationship between TGR and overall survival. From 2000-2019, the study cohort comprised 38, 60, and 47 HBV, HCV, and NAFLD patients, respectively, with TGRs. NAFLD-HCC tumor size was inversely correlated to the extent of liver disease as measured by Child-Pugh score (7.2 cm in non-cirrhosis; 3.7 cm, 2.6 cm, and 2.1 cm in Child A, B, and C, respectively; NAFLD-HCC patients have more indolent growths than viral-related HCC TGRs. The addition of TGR as a biomarker may assist in stratifying treatment options.
Identifiants
pubmed: 34966854
doi: 10.20517/2394-5079.2021.74
pmc: PMC8713558
mid: NIHMS1760040
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK041301
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of interest All authors declared that there are no conflicts of interest.
Références
Hepatogastroenterology. 1998 Aug;45 Suppl 3:1214-20
pubmed: 9730377
J Hepatol. 2015 Nov;63(5):1156-63
pubmed: 26100498
Gastroenterology. 2020 Nov;159(5):1985-1987.e4
pubmed: 32763241
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238
pubmed: 33349658
Hepatology. 2015 Dec;62(6):1723-30
pubmed: 26274335
AJR Am J Roentgenol. 1984 Apr;142(4):851-2
pubmed: 6608255
Cancer. 1961 Nov-Dec;14:1272-94
pubmed: 13909709
Hepatology. 2020 Nov;72(5):1654-1665
pubmed: 32017165
Transplantation. 2017 Sep;101(9):2071-2078
pubmed: 28353492
JAMA Oncol. 2018 Dec 1;4(12):1683-1690
pubmed: 30286235
Clin Mol Hepatol. 2015 Sep;21(3):279-86
pubmed: 26523271
Hepatology. 2020 Mar;71(3):808-819
pubmed: 31675427
Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58
pubmed: 20628345
Sci Rep. 2020 Jun 18;10(1):9902
pubmed: 32555268
Hepatol Commun. 2020 Apr 24;4(6):825-833
pubmed: 32490319
PLoS Med. 2014 Apr 01;11(4):e1001624
pubmed: 24691105
Cell. 2018 Nov 15;175(5):1289-1306.e20
pubmed: 30454647
Gastroenterology. 1985 Aug;89(2):259-66
pubmed: 2408960
Ann Intern Med. 2019 Sep 3;171(5):318-327
pubmed: 31426090
Hepatology. 1992 Jul;16(1):132-7
pubmed: 1352268
Hepatol Commun. 2017 Jun 21;1(7):595-608
pubmed: 29404481
Aliment Pharmacol Ther. 2017 Jan;45(1):169-177
pubmed: 27862091
Gut. 2021 Feb;70(2):401-407
pubmed: 32398224
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
Ann Behav Med. 2003 Dec;26(3):172-81
pubmed: 14644693
Clin Liver Dis (Hoboken). 2016 May 27;7(5):97-100
pubmed: 31041039
Hepatology. 2017 Mar;65(3):864-874
pubmed: 27531119
Hepatology. 2021 Jan;73 Suppl 1:115-127
pubmed: 32045030
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Radiology. 2011 Jun;259(3):730-8
pubmed: 21364083
JAMA Oncol. 2017 Apr 1;3(4):493-500
pubmed: 27838698
Dig Dis Sci. 2021 Jul;66(7):2394-2406
pubmed: 32654086
World J Gastroenterol. 2010 Nov 14;16(42):5286-96
pubmed: 21072891